Abstract
Background: Disparities in colorectal cancer (CRC) outcomes may be due to a more aggressive phenotype in African American patients in the setting of decreased tumor immunity. This study compares the immunogenomic signatures of CRC from African American (AA) and European American (EA) patients to explore underlying molecular factors.
Methods: Data from 254 CRC patients (58 AA, 196 EA) were identified from The Cancer Genome Atlas (TCGA). Immunophenotype signatures were established using cellular deconvolution, and comparisons were made regarding survival and immune cellular components, controlling for sex, age, and disease stage.
Results: AA patients exhibited decreased progression-free survival (p=0.04). Tumors from AA patients showed a reduced fraction of macrophages and CD8+ T cells and an increased fraction of B cells compared to EA patients. Immunostimulatory and immunoinhibitory gene profiles also differed significantly by race.
Conclusions: Differences in the tumor immune microenvironment (TME) may contribute to survival disparities and provide targeted therapeutic opportunities.
Introduction
In the United States, African Americans face a 30–50% higher mortality rate from colorectal cancer compared to European Americans. While socioeconomic factors are critical, approximately 25% of this survival disparity remains unexplained. This research investigates whether the "missing link" lies in the biological composition of the tumor microenvironment (TME), specifically how the immune system recognizes and attacks cancer cells across different racial groups.
Methods and Data Sources
The study utilized publicly available data from The Cancer Genome Atlas (TCGA), specifically the colorectal adenocarcinoma (COAD/READ) datasets. The researchers employed CIBERSORT, a cellular deconvolution tool, to estimate the proportions of 22 immune cell types from bulk gene expression profiles. Statistical significance was determined using multivariable linear regression to account for potential confounders like age, sex, and cancer stage.
Key Results
Survival and Cellular Disparities
African American patients demonstrated significantly lower progression-free survival (p=0.04), with a median of 1,678 days compared to EA patients, whose median was not reached during the study period. Analysis of the TME revealed that AA tumors are often "immunologically cold."
As shown in the data, AA tumors had a significantly reduced fraction of CD8+ T cells (0.10 vs 0.12, p=0.03) and macrophages (0.34 vs 0.40, p=0.003). Conversely, they exhibited a higher fraction of B cells (0.08 vs 0.05, p=0.002).
Molecular Signatures and Gene Expression
The study identified a critical downregulation of antigen-presentation machinery in AA tumors. Specifically, molecules like MHC Class I and II, which are essential for T cell recognition, were expressed at lower levels. Furthermore, several key "checkpoint" and immunostimulatory genes were found to be downregulated in the AA cohort.
Notable downregulated genes include PDCD1 (PD-1), CD274 (PD-L1), and LAG3. While these are common targets for immunotherapy, their low baseline expression in AA patients suggests a fundamentally different immune exhaustion profile and potentially different responses to standard checkpoint inhibitors.
Discussion and Future Directions
The findings suggest that the "colder" immune microenvironment in African American CRC patients—characterized by fewer killer T cells and impaired antigen presentation—may drive more aggressive disease progression.
However, the study is limited by the relatively small sample size of AA patients in the TCGA (n=58) and a lack of granular socioeconomic data. Future research using spatial transcriptomics is necessary to determine if immune cells are successfully penetrating the tumor core or remaining sequestered in the stroma. These biological insights underscore the need for clinical trials that incorporate race-specific biomarkers to optimize therapeutic outcomes for all patient populations.
Summary updated